Literature DB >> 33139382

Acid Ceramidase Rescues Cystic Fibrosis Mice from Pulmonary Infections.

Katrin Anne Becker1, Rabea Verhaegh1, Hedda-Luise Verhasselt2, Simone Keitsch1, Matthias Soddemann1, Barbara Wilker1, Gregory C Wilson3, Jan Buer2, Syed A Ahmad3, Michael J Edwards3, Erich Gulbins4,3.   

Abstract

Previous studies have shown that sphingosine kills a variety of pathogenic bacteria, including Pseudomonas aeruginosa and Staphylococcus aureus Sphingosine concentrations are decreased in airway epithelial cells of cystic fibrosis (CF) mice, and this defect has been linked to the infection susceptibility of these mice. Here, we tested whether the genetic overexpression of acid ceramidase rescues cystic fibrosis mice from pulmonary infections with P. aeruginosa We demonstrate that the transgenic overexpression of acid ceramidase in CF mice corresponds to the overexpression of acid ceramidase in bronchial and tracheal epithelial cells and normalizes ceramide and sphingosine levels in bronchial and tracheal epithelial cells. In addition, the expression of β1-integrin, which is ectopically expressed on the luminal surface of airway epithelial cells in cystic fibrosis mice, an alteration that is very important for mediating pulmonary P. aeruginosa infections in cystic fibrosis, is normalized in cystic fibrosis airways upon the overexpression of acid ceramidase. Most importantly, the overexpression of acid ceramidase protects cystic fibrosis mice from pulmonary P. aeruginosa infections. Infection of CF mice or CF mice that inhaled sphingosine with P. aeruginosa or a P. aeruginosa mutant that is resistant to sphingosine indicates that sphingosine and not a metabolite kills P. aeruginosa upon pulmonary infection. These studies further support the use of acid ceramidase and its metabolite sphingosine as potential treatments of cystic fibrosis.
Copyright © 2021 Becker et al.

Entities:  

Keywords:  Pseudomonas aeruginosazzm321990; acid ceramidase; ceramide; cystic fibrosis; pneumonia; sphingosine

Mesh:

Substances:

Year:  2021        PMID: 33139382      PMCID: PMC7822142          DOI: 10.1128/IAI.00677-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Antimicrobial activity of sphingosines.

Authors:  D J Bibel; R Aly; H R Shinefield
Journal:  J Invest Dermatol       Date:  1992-03       Impact factor: 8.551

2.  Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis.

Authors:  Manish Bodas; Garrett Pehote; David Silverberg; Erich Gulbins; Neeraj Vij
Journal:  Free Radic Biol Med       Date:  2018-11-28       Impact factor: 7.376

3.  Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease.

Authors:  Malcolm Brodlie; Michael C McKean; Gail E Johnson; Joe Gray; Andrew J Fisher; Paul A Corris; James L Lordan; Christopher Ward
Journal:  Am J Respir Crit Care Med       Date:  2010-04-15       Impact factor: 21.405

4.  Lack of Sphingosine Causes Susceptibility to Pulmonary Staphylococcus Aureus Infections in Cystic Fibrosis.

Authors:  Shaghayegh Tavakoli Tabazavareh; Aaron Seitz; Peter Jernigan; Carolin Sehl; Simone Keitsch; Stephan Lang; Barbara C Kahl; Michael Edwards; Heike Grassmé; Erich Gulbins; Katrin Anne Becker
Journal:  Cell Physiol Biochem       Date:  2016-05-17

5.  Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.

Authors:  H Matsui; B R Grubb; R Tarran; S H Randell; J T Gatzy; C W Davis; R C Boucher
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

6.  Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.

Authors:  Katrin Anne Becker; Joachim Riethmüller; Anja Lüth; Gerd Döring; Burkhard Kleuser; Erich Gulbins
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-27       Impact factor: 6.914

Review 7.  Cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  Lancet       Date:  2016-04-29       Impact factor: 79.321

8.  Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.

Authors:  Landon W Locke; Michael M Myerburg; Daniel J Weiner; Matthew R Markovetz; Robert S Parker; Ashok Muthukrishnan; Lawrence Weber; Michael R Czachowski; Ryan T Lacy; Joseph M Pilewski; Timothy E Corcoran
Journal:  Eur Respir J       Date:  2016-03-23       Impact factor: 16.671

9.  Spontaneous rescue from cystic fibrosis in a mouse model.

Authors:  Nikoletta Charizopoulou; Martina Wilke; Martina Dorsch; Alice Bot; Huub Jorna; Silke Jansen; Frauke Stanke; Hans J Hedrich; Hugo R de Jonge; Burkhard Tümmler
Journal:  BMC Genet       Date:  2006-03-29       Impact factor: 2.797

10.  Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta.

Authors:  Nara Liessi; Emanuela Pesce; Clarissa Braccia; Sine Mandrup Bertozzi; Alessandro Giraudo; Tiziano Bandiera; Nicoletta Pedemonte; Andrea Armirotti
Journal:  JCI Insight       Date:  2020-08-20
View more
  2 in total

1.  Interferon regulatory factor 8 regulates expression of acid ceramidase and infection susceptibility in cystic fibrosis.

Authors:  Aaron Ions Gardner; Yuqing Wu; Rabea Verhaegh; Yongjie Liu; Barbara Wilker; Matthias Soddemann; Simone Keitsch; Michael J Edwards; Iram J Haq; Markus Kamler; Katrin Anne Becker; Malcolm Brodlie; Erich Gulbins
Journal:  J Biol Chem       Date:  2021-04-09       Impact factor: 5.157

2.  The acid ceramidase/ceramide axis controls parasitemia in Plasmodium yoelii-infected mice by regulating erythropoiesis.

Authors:  Anne Günther; Matthias Hose; Hanna Abberger; Fabian Schumacher; Ylva Veith; Burkhard Kleuser; Kai Matuschewski; Karl Sebastian Lang; Erich Gulbins; Jan Buer; Astrid M Westendorf; Wiebke Hansen
Journal:  Elife       Date:  2022-09-12       Impact factor: 8.713

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.